According to Rohto’s business strategy, adipose-derived stem cells will be a crucial element to develop products for liver cirrhosis and lung fibrosis.
Nikkei Biotech news release, March 1, 2016
Rohto Pharmaceutical to look for approval of refractory fibrosis by stem-cell technology